Skip to content

Advancements in Migraine Therapeutics

The evidence-based recommendation of triptans to treat migraine offers relief for some patients but is not optimal for others and can lead to adverse outcomes in some patients. The introduction of calcitonin gene-related peptide receptor antagonists and monoclonal antibodies has provided a new avenue for acute and chronic migraine management, providing an alternative for patients experiencing medication overuse, triptan intolerance, or contraindications.

Learning Objectives

Upon completion of this activity, the participant will be able to:

  • Describe the underlying pathology of a migraine and the role of neuropeptides in the pathological process
  • Describe step-care and stratified-care models in the management of a migraine patient
  • Explain the role of CGRP receptor antagonists and monoclonal antibodies in the treatment of migraine
  • Discuss the benefits of triptans for acute migraine management


Steven J. Crosby, M.A., B.S.P., R.Ph
Steven J. Crosby, M.A., B.S.P., R.Ph., FASCP is a member of the School of Pharmacy-Boston Executive Council, serving as the Assistant Dean of Student Engagement and Success. Steven maintains faculty appointments as an Associate Professor of Pharmacy Practice for MCPHS, and as a Lecturer in Psychiatry for the Boston University School of Medicine. He holds degrees in pharmacy, from MCPHS, and in medical science, from the BU School of Medicine. As a pharmacist, he has practiced in community, rehabilitation hospital, and academic research settings. He maintains research expertise in the areas of behavioral pharmacology, experimental therapeutics, neuroscience, and the scholarship of teaching, publishing in the areas of neuroscience, clinical medicine, pharmacy education and practice, and serving as an author on more than 30 national presentations. His research has been cited in more than 20 peer-reviewed journals, including Frontiers in Psychiatry, the British Journal of Pharmacology, Neuropsychopharmacology, the American Journal of Drug and Alcohol Abuse, and Clinical Neuropharmacology. He serves as an Associate Editor for Clinical Case Reports, with Editorial Board appointments for The Consultant Pharmacist and the American Journal of Health-System Pharmacy. Research experience has led to peer reviewer appointments for more than 15 professional journals. He serves as a consultant to the National Association of Boards of Pharmacy. He is the Chair of the education compliance subcommittee for the American College of Clinical Pharmacology, and has served as the past Chair of the pharmacy practice scholarship and research development committee for the American Association of Colleges of Pharmacy. He is an elected councilor of the American Federation for Medical Research-Eastern Section, and a research grant reviewer for the American Association of Colleges of Pharmacy.


ACPE logo

Release Date: October 21, 2020
Expiration Date: October 21, 2022
Contact Hours: 1.0
Universal Activity Number: ACPE UAN: 0026-0000-20-203-H01-P | Knowledge-based
ACPE Topic Designator: Disease State Management/Drug Therapy

Registration Fee: Free to MCPHS Alumni and full-time employees; $12.00 for all other professionals.